- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05334927
China HeadAche DIsorders RegiStry (CHAIRS)
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Yong Gang Wang, Doctor
- Phone Number: 086 15010066622
- Email: w100yg@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 12 years old,Any gender;
- The first onset age of primary headache was less than 50 years old(Age <65 years at first diagnosis of chronic migraine);
- patients with primary headache (migraine, tension headache and other types of primary headache) or primary headache complicated with MOH according to ICHD-3;
- Sign the informed consent form.
Exclusion Criteria:
- According to the ICHD-3 diagnostic criteria, there are still headaches directly related to secondary factors (except drug overuse) at the time of enrollment;
- Those who cannot be diagnosed as primary headache or primary headache combined with medication overuse headache according to ICHD-3;
- According to DSM-V diagnostic criteria, patients with severe mental diseases (such as schizophrenia, mental disorders associated with mental retardation, etc.);
- Patients with severe organic diseases, such as malignant tumors, and the expected survival time is less than 1 year;
- Pregnant,planning pregnancy or Lactating women;
- Subjects participating in other clinical trials;
- Unable to cooperate to complete the follow-up due to geographical or other reasons
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Medicine Overuse Headache/New Daily Persistent Headache
The first 18 months were followed up once a month,then followed up once at the 24th month,follow-up visits were made annually after 24 months
|
At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
|
Chronic Migraine
The patients were followed up at 1, 2, 3, 6, 9, 12, 18 and 24 months,then follow-up visits were made annually
|
long-term follow-up
|
Patients with other types of primary headache
The patients were followed up at 3, 6, 9months
|
No collection Brain imaging、Cognitive function test、Biological sample
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Headache Days
Time Frame: long term: 10 years
|
The number of days of headache is the number of days in which headache occurs.
|
long term: 10 years
|
MRI change
Time Frame: long term: 10 years
|
Patients will accept MRI scans will be done at baseline and once per year.
|
long term: 10 years
|
Genetic analysis of familial headache
Time Frame: 1 year
|
Blood samples will be collected from all participants who consent to participate in the study, for the purposes of genetic analysis of familial headache.
|
1 year
|
Montreal Cognitive Assessment (MoCA)
Time Frame: long term: 10 years
|
The Montreal Cognitive Assessment (MoCA) will be used to assess changes in cognitive functions.
|
long term: 10 years
|
Mini-Mental State Exam (MMSE)
Time Frame: long term: 10 years
|
The Mini-Mental State Examination (MMSE) is a 30-point questionnaire that is used in clinical and research settings to assess cognitive function.
|
long term: 10 years
|
Migraine Disability Assessment (MIDAS)
Time Frame: long term: 10 years
|
The MIDAS is a 7-item questionnaire designed to quantify headache-related disability over a 3- month period.
The MIDAS score is the sum of missed work or school days, days at work or school plus days of household work where productivity was reduced by half or more, missed household work days, and missed non-work activity days due to headaches in the last 3 months.
|
long term: 10 years
|
Generalized Anxiety Disorder (GAD-7)
Time Frame: long term: 10 years
|
GAD-7 is a proven, self-administered and concise tool for screening and diagnosing mental health disorders, which has been tested in the field in office practice.
The GAD-7 scale score ranges from 0 to 21.
|
long term: 10 years
|
Patient Health Questionnaire (PHQ)-9
Time Frame: long term: 10 years
|
The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day).
A PHQ-9 score total of 0-4 points equals "normal" or minimal depression.
Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression.
|
long term: 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Social and demographic data, medical history
Time Frame: long term: 10 years
|
Social and demographic data, medical and medication history will be collected at initial screening.
|
long term: 10 years
|
Use of Rescue Medication
Time Frame: long term: 10 years
|
Frequency of Rescue medication will be collected by eDiary.
|
long term: 10 years
|
Moderate / Severe Headache Days
Time Frame: long term: 10 years
|
Moderate / severe headache days are defined as a day in which moderate or severe pain persists for at least 4 hours, or headache lasts for one day after successful medication for acute headache.
These definitions allow the use of relatively simple headache diaries.
Subjects were required to indicate whether headache was present (yes / no), peak (mild / moderate / severe) severity and duration (< 4h or 4h), type of acute drug intake, and response to treatment should also be recorded.
|
long term: 10 years
|
Pain severity
Time Frame: long term: 10 years
|
Pain severity were captured through Visual analogue scale (VAS) for pain, a continuous scale comprised of a horizontal line, anchored by "no pain" (score of 0) and "worst imaginable pain" (score of 10).
|
long term: 10 years
|
MEG
Time Frame: long term: 10 years
|
Patients will accept MEG.
|
long term: 10 years
|
PET
Time Frame: long term: 10 years
|
Patients will accept PET scan.
|
long term: 10 years
|
EEG
Time Frame: long term: 10 years
|
Patients will accept EEG scan.
|
long term: 10 years
|
Proteomics
Time Frame: 1 year
|
Blood, urine and Cerebrospinal fluid samples will be collected from all participants who consent to participate in the study, for the purposes of Proteomics at baseline and month 12.
|
1 year
|
Microbiome
Time Frame: 1 year
|
Saliva samples will be collected from all participants who consent to participate in the study, for the purposes of Microbiome at baseline and month 12.
|
1 year
|
Headache Impact Test (HIT-6)
Time Frame: long term: 10 years
|
The HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant's ability to function on the job, at school, at home, and in social situations.
It assesses the effect that headaches have on normal daily life and the participant's ability to function.
|
long term: 10 years
|
European Quality of Life 5 Dimensions 3 Level Version (EQ-5D-3L)
Time Frame: long term: 10 years
|
EQ-5D-3L is a generic instrument for use as a measure of health status. The EQ-5D-3L consists of 2 components-the EQ-5D descriptive system and the EQ VAS. The descriptive system comprises of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. The EQ VAS records the respondent's self-rated health on a vertical, VAS where the endpoints are labelled "Best imaginable health state" and "Worst imaginable health state." The scoring range of the EQ VAS is from 0 (worst imaginable health) to 100 (best imaginable health). |
long term: 10 years
|
Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1)
Time Frame: long term: 10 years
|
The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality-of-life impairments attributed to migraine in the past 4 weeks.
It is divided into 3 domains: Role Function Restrictive assesses how migraines limit one's daily social and work-related activities; Role Function Preventive assesses how migraines prevent these activities; and the Emotional Function domain assesses the emotions associated with migraines.
|
long term: 10 years
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: long term: 10 years
|
The Pittsburgh Sleep Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep.
|
long term: 10 years
|
Columbia-Suicide Severity Rating Scale
Time Frame: long term: 10 years
|
C-SSRS will be administered to study subjects at each study visit to assess possible suicidal ideation and behavior.
Reports of suicidal ideation with intent to act (endorse item 4 or 5) and reports of actual, aborted, or interrupted suicide attempts or a behavior preparatory for making an attempt indicate subjects at high risk for suicide.
|
long term: 10 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY2022-tt02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Medicine Overuse Headache/New Daily Persistent Headache
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); Arizona State...RecruitingHealthy | Post-Traumatic HeadacheUnited States
-
Indonesia UniversityWageningen University; SEAMEO Regional Centre for Food and NutritionCompletedDepression | Obesity | Insulin Resistance | Dyslipidemias | Behavior | Stunting | Cognitive Function 1, Social | Permeability; IncreasedIndonesia
-
Ohio State UniversityMassachusetts General Hospital; University of Wisconsin, Madison; University...CompletedMigraine HeadachesUnited States
-
Hacettepe UniversityCompletedQuality of Life | Physical Disability | Psychosocial Problem | Meniere DiseaseTurkey